论文部分内容阅读
对２２例用１５３Ｓｍ－ＥＤＴＭＰ治疗癌性骨痛的患者进行骨照射吸收剂量分析以了解剂量－响应因素。２２例中疗效显著组１７例，无效组５例。结果表明两组间尿的累积活度、骨摄取率和单位注射剂量的骨累积活度（ｋＢｑ·ｈ／ＭＢｑ）差异均显著（Ｐ＜０．０１）。但骨的吸收活度和累积活度两组间无显著差异（Ｐ＞０．０５）。显效组红骨髓的吸收剂量为２１３．７７ｃＧｙ，无效组为１６２．０９ｃＧｙ，两组无显著差异（Ｐ＞０．０５），均在安全剂量范围。结果提示对骨的相对剂量分布的分析有助于进一步阐明剂量－响应关系。
Twenty-two patients with cancerous bone pain treated with 153Sm-EDTMP were analyzed for absorbed bone doses to understand dose-response factors. Among the 22 cases, 17 cases were significantly effective, and 5 cases were ineffective. The results showed that the cumulative activity of urine, bone uptake rate, and bone cumulative activity (kBq·h/MBq) were significantly different between the two groups (P<0.01). However, there was no significant difference between the two groups in bone resorption activity and cumulative activity (P>0.05). The absorbed dose of erythrocytic bone marrow in the markedly effective group was 213.77 cGy, and that in the ineffective group was 162.09 cGy. There was no significant difference between the two groups (P>0.05). Both doses were in safe dose range. The results suggest that analysis of the relative dose distribution of bones helps to further clarify the dose-response relationship.